Enhanced Genomics’ decision to extend its Series A funding round has resulted in a total Series A funding raise of $19million.
The biotechnology company is pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases.
CEO Hazel Jones with Enhanced Genomics team in The Jeffreys Building, St John’s Innovation Centre. Picture: Keith Heppell
By translating massive amounts of disease-associated data into actionable insights, Enhanced identifies high-confidence targets with strong genetic evidence of causality, increasing the probability of success in drug development in a fraction of the time and cost previously possible.
The funding will be used to expand Enhanced’s internal therapeutic pipeline in common diseases, including autoimmune conditions such as inflammatory bowel disease.
“Our founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets,” said Dietrich Stephan, chair, Enhanced Genomics.
Dietrich Stephan, chair, Enhanced Genomics
“We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies.
“This puts us in a strong position to lead the next major shift in pharma. When developing a novel approach to drug discovery, clarity of thought and courage are required to build deep conviction, and we are proud to have built a team that embodies this. We thank our investors for continuing to support our vision.”